New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures.

Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction. CMAJ (2003) 1.03

Primary angioplasty for ST-segment elevation myocardial infarction: ready for prime time? CMAJ (2003) 0.98

CYPHER coronary stents and risk of thrombosis. CMAJ (2003) 0.79

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med (1994) 9.15

Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med (1998) 5.61

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med (1998) 5.41

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med (1993) 4.92

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med (1998) 4.68

Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med (1999) 4.37

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med (1994) 3.96

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med (2001) 3.85

Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med (1997) 3.25

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet (2000) 2.99

Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med (2000) 2.84

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med (1998) 2.73

Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation (1997) 2.70

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 2.27

Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet (2000) 2.15

New advances in the management of acute coronary syndromes: 1. Matching treatment to risk. CMAJ (2001) 2.12

One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10

Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med (1999) 2.02

Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation (1998) 1.87

Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation (1994) 1.82

Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1998) 1.65

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation (1998) 1.63

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med (1999) 1.55

One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol (1995) 1.25

Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation (1999) 1.21

Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. Circulation (1999) 1.04

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation (1999) 0.92

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol (1997) 0.90

Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation (2006) 3.94

Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation (2010) 3.65

Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation (2007) 3.44

Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation (2006) 2.88

Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. Eur J Cardiothorac Surg (2006) 2.61

Prevention and management of transcatheter balloon-expandable aortic valve malposition. Catheter Cardiovasc Interv (2008) 1.98

Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg (2006) 1.91

Red blood cell storage duration and mortality in patients undergoing percutaneous coronary intervention. Am Heart J (2010) 1.65

Transatrial transcatheter tricuspid valve-in-valve implantation of balloon expandable bioprosthesis. Ann Thorac Surg (2010) 1.57

Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv (2009) 1.54

Stenting for coronary artery spasm. Catheter Cardiovasc Interv (2002) 1.50

Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol (2009) 1.50

Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol (2003) 1.44

Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41

Technical considerations to avoid pitfalls during transapical aortic valve implantation. J Thorac Cardiovasc Surg (2010) 1.21

Transapical transcatheter aortic valve implantation: follow-up to 3 years. J Thorac Cardiovasc Surg (2010) 1.16

Transapical transcatheter mitral valve-in-valve implantation in a human. Ann Thorac Surg (2009) 0.99

Revascularization use and survival outcomes after cardiac catheterization in British Columbia and Alberta. Can J Cardiol (2004) 0.97

Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients. J Thorac Cardiovasc Surg (2008) 0.92

Population rates of invasive cardiac procedures in British Columbia, 1995 to 2001. Can J Cardiol (2004) 0.89

Mitral valve injury late after transcatheter aortic valve implantation. J Thorac Cardiovasc Surg (2009) 0.88

A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. Can J Cardiol (2004) 0.83

Changing outcomes of coronary revascularization in British Columbia, 1995-2001. Can J Cardiol (2006) 0.82

CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement. Swiss Med Wkly (2009) 0.82

Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years. Am Heart J (2009) 0.82

Pathology of transcatheter valve therapy. JACC Cardiovasc Interv (2012) 0.81

Effect of percutaneous coronary intervention of nonacute total coronary artery occlusions on QT dispersion. Am Heart J (2006) 0.80

Cross-provincial use of cardiac services: the importance of data-sharing for clinical registries and outcomes research. Can J Cardiol (2005) 0.80

Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study. Can J Cardiol (2009) 0.78

Current balloon-expandable transcatheter heart valve and delivery systems. Catheter Cardiovasc Interv (2010) 0.78

An unusual complication of coil embolization of a large coronary-pulmonary fistula. J Invasive Cardiol (2003) 0.76

Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention. Int J Cardiol (2011) 0.76

Customized covered stent graft for percutaneous closure of Fontan baffle leak. J Invasive Cardiol (2013) 0.75

Transcatheter valve-in-valve aortic valve implantation: 16-month follow-up. Ann Thorac Surg (2009) 0.75

Procedural efficacy and complications of X-Sizer thrombectomy in de novo and stented lesions. Catheter Cardiovasc Interv (2004) 0.75

A proposed clinical model for efficient utilization of invasive coronary angiography. Am J Cardiol (2010) 0.75

Percutaneous occlusion of a pulmonary aneurysm causing hemoptysis in a patient with pulmonary atresia and aortopulmonary collaterals. Catheter Cardiovasc Interv (2005) 0.75

Safety and cost benefit of same-day discharge after percutaneous coronary intervention. Am J Cardiol (2002) 0.75

First-in-man use of a tapered endovascular stent graft for treatment of aneurysm after coarctation repair. Catheter Cardiovasc Interv (2010) 0.75